Raphael Bigler

Title: Raphael Bigler: Innovator in Pharmaceutical Chemistry

Introduction

Raphael Bigler is a notable inventor based in Aargau, Switzerland. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the synthesis of complex compounds. His work has led to advancements in the development of pan-RAF inhibitors, which are crucial in cancer treatment.

Latest Patents

Raphael Bigler holds a patent for the synthesis of a bis-mesylate salt of 4-amino-N-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide. This manufacturing process features several efficient key reactions, including a robust and scalable Pd-catalyzed carbonylation reaction. The process also includes a highly chemoselective Pt/V/C-catalyzed nitro group reduction, leading to the production of a compound with upwards of 95% purity.

Career Highlights

Throughout his career, Raphael Bigler has worked with prominent companies in the pharmaceutical industry, including Hoffmann-La Roche Inc. and Genentech, Inc. His expertise in chemical synthesis and process development has been instrumental in advancing drug formulations.

Collaborations

Raphael has collaborated with esteemed colleagues such as Eduardo V Mercado-Marin and Michael Dalziel. These partnerships have fostered innovation and contributed to the successful development of new pharmaceutical compounds.

Conclusion

Raphael Bigler's contributions to pharmaceutical chemistry and his innovative patent demonstrate his commitment to advancing medical science. His work continues to impact the field positively, paving the way for future developments in cancer treatment.